Literature DB >> 201475

Neurotensin administered intracisternally inhibits responsiveness of mice to noxious stimuli.

B V Clineschmidt, J C McGuffin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 201475     DOI： 10.1016/0014-2999(77)90236-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN： 0014-2999            Impact factor:   4.432


× No keyword cloud information.
  21 in total

1.  Structure of neurolysin reveals a deep channel that limits substrate access.

Authors:  C K Brown; K Madauss; W Lian; M R Beck; W D Tolbert; D W Rodgers
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-06       Impact factor: 11.205

Review 2.  The role of neurotensin in central nervous system pathophysiology: what is the evidence?

Authors:  Fannie St-Gelais; Claudia Jomphe; Louis-Eric Trudeau
Journal:  J Psychiatry Neurosci       Date:  2006-07       Impact factor: 6.186

3.  Identification and functional characterization of a stable, centrally active derivative of the neurotensin (8-13) fragment as a potential first-in-class analgesic.

Authors:  Francis M Hughes; Brooke E Shaner; Lisa A May; Lyndsay Zotian; Justin O Brower; R Jeremy Woods; Michael Cash; Dustin Morrow; Fabienne Massa; Jean Mazella; Thomas A Dix
Journal:  J Med Chem       Date:  2010-06-24       Impact factor: 7.446

4.  Systemically and topically active antinociceptive neurotensin compounds.

Authors:  Grace C Rossi; Joshua E Matulonis; Elliott Richelson; Denise Barbut; Gavril W Pasternak
Journal:  J Pharmacol Exp Ther       Date:  2010-06-24       Impact factor: 4.030

5.  Structure-antinociceptive activity studies with neurotensin.

Authors:  S Furuta; K Kisara; S Sakurada; T Sakurada; Y Sasaki; K Suzuki
Journal:  Br J Pharmacol       Date:  1984-09       Impact factor: 8.739

6.  Identification of N-{[6-chloro-4-(2,6-dimethoxyphenyl)quinazolin-2-yl]carbonyl}-l-leucine (NTRC-808), a novel nonpeptide chemotype selective for the neurotensin receptor type 2.

Authors:  James B Thomas; Angela M Giddings; Srinivas Olepu; Robert W Wiethe; Danni L Harris; Sanju Narayanan; Keith R Warner; Philippe Sarret; Jean-Michel Longpre; Scott P Runyon; Brian P Gilmour
Journal:  Bioorg Med Chem Lett       Date:  2014-11-24       Impact factor: 2.823

7.  In Search of the Optimal Macrocyclization Site for Neurotensin.

Authors:  Marc Sousbie; Élie Besserer-Offroy; Rebecca L Brouillette; Jean-Michel Longpré; Richard Leduc; Philippe Sarret; Éric Marsault
Journal:  ACS Med Chem Lett       Date:  2018-01-29       Impact factor: 4.345

8.  Neurotensin and its amide analogue [Gln4]-neurotensin: effects on brain monoamine turnover.

Authors:  J A García-Sevilla; T Magnusson; A Carlsson; J Leban; K Folkers
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-12       Impact factor: 3.000

9.  Alterations in nociception and body temperature after intracisternal administration of neurotensin, beta-endorphin, other endogenous peptides, and morphine.

Authors:  C B Nemeroff; A J Osbahr; P J Manberg; G N Ervin; A J Prange
Journal:  Proc Natl Acad Sci U S A       Date:  1979-10       Impact factor: 11.205

10.  Neurotensin inhibition of GABAergic transmission via mGluR-induced endocannabinoid signalling in rat periaqueductal grey.

Authors:  V A Mitchell; H Kawahara; C W Vaughan
Journal:  J Physiol       Date:  2009-04-09       Impact factor: 5.182
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.